Pain Therapeutics, Inc. (NASDAQ:PTIE) – Equities research analysts at Gabelli increased their FY2017 EPS estimates for Pain Therapeutics in a research note issued to investors on Wednesday. Gabelli analyst K. Kedra now forecasts that the biopharmaceutical company will post earnings per share of ($1.90) for the year, up from their previous forecast of ($2.20). Gabelli also issued estimates for Pain Therapeutics’ FY2018 earnings at ($2.50) EPS, FY2019 earnings at ($5.00) EPS, FY2020 earnings at ($4.70) EPS and FY2021 earnings at ($3.50) EPS.

A number of other analysts have also recently commented on the stock. Zacks Investment Research upgraded shares of Pain Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research report on Tuesday, October 31st. ValuEngine cut shares of Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.

Pain Therapeutics (PTIE) opened at $8.51 on Friday. The firm has a market capitalization of $56.13, a price-to-earnings ratio of -4.63 and a beta of 2.11. Pain Therapeutics has a 12 month low of $3.10 and a 12 month high of $12.80.

Pain Therapeutics (NASDAQ:PTIE) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter.

An institutional investor recently bought a new position in Pain Therapeutics stock. Dimensional Fund Advisors LP bought a new position in shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned approximately 0.91% of Pain Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 35.99% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Gabelli Analysts Raise Earnings Estimates for Pain Therapeutics, Inc. (PTIE)” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/12/gabelli-analysts-raise-earnings-estimates-for-pain-therapeutics-inc-ptie.html.

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Earnings History and Estimates for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.